A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes

被引:338
作者
Flora, Gagan D. [1 ]
Nayak, Manasa K. [1 ]
机构
[1] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
关键词
Atherosclerosis; hypertension; thrombosis; stroke; platelets; epidemiological studies; SUBTILISIN/KEXIN TYPE 9; CORONARY-ARTERY-DISEASE; BILE-ACID SEQUESTRANTS; FACTOR XA INHIBITORS; ASPIRIN PLUS DIPYRIDAMOLE; ED AMERICAN-COLLEGE; N-3; FATTY-ACIDS; VENOUS THROMBOEMBOLISM; ANTIPLATELET THERAPY; BLOOD-PRESSURE;
D O I
10.2174/1381612825666190925163827
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardiovascular diseases (CVDs) are the leading cause of premature death and disability in humans and their incidence is on the rise globally. Given their substantial contribution towards the escalating costs of health care, CVDs also generate a high socio-economic burden in the general population. The underlying pathogenesis and progression associated with nearly all CVDs are predominantly of atherosclerotic origin that leads to the development of coronary artery disease, cerebrovascular disease, venous thromboembolism and, peripheral vascular disease, subsequently causing myocardial infarction, cardiac arrhythmias or stroke. The aetiological risk factors leading to the onset of CVDs are well recognized and include hyperlipidaemia, hypertension, diabetes, obesity, smoking and, lack of physical activity. They collectively represent more than 90% of the CVD risks in all epidemiological studies. Despite high fatality rate of CVDs, the identification and careful prevention of the underlying risk factors can significantly reduce the global epidemic of CVDs. Beside making favorable lifestyle modifications, primary regimes for the prevention and treatment of CVDs include lipid-lowering drugs, antihypertensives, antiplatelet and anticoagulation therapies. Despite their effectiveness, significant gaps in the treatment of CVDs remain. In this review, we discuss the epidemiology and pathology of the major CVDs that are prevalent globally. We also determine the contribution of well-recognized risk factors towards the development of CVDs and the prevention strategies. In the end, therapies for the control and treatment of CVDs are discussed.
引用
收藏
页码:4063 / 4084
页数:22
相关论文
共 263 条
[1]   Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Ageno, Walter ;
Gallus, Alexander S. ;
Wittkowsky, Ann ;
Crowther, Mark ;
Hylek, Elaine M. ;
Palareti, Gualtiero .
CHEST, 2012, 141 (02) :E44S-E88S
[2]   Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets - In vitro and in vivo/ex vivo studies [J].
Aktas, B ;
Utz, A ;
Hoenig-Liedl, P ;
Walter, U ;
Geiger, J .
STROKE, 2003, 34 (03) :764-769
[3]   Pharmacological strategies for inhibition of thrombin activity [J].
Alban, S. .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (12) :1152-1175
[4]   Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs [J].
Ali, Ferhana Y. ;
Armstrong, Paul C. J. ;
Dhanji, Al-Rehan A. ;
Tucker, Arthur T. ;
Paul-Clark, Mark J. ;
Mitchell, Jane A. ;
Warner, Timothy D. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (05) :706-711
[5]   The Effects of Diuretics on Mineral and Bone Metabolism [J].
Alon, Uri S. .
PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2018, 15 (04) :291-297
[6]   Management of raised intracranial pressure in aneurysmal subarachnoid hemorrhage: time for a consensus? [J].
Alotaibi, Naif M. ;
Wang, Justin Z. ;
Pasarikovski, Christopher R. ;
Guha, Daipayan ;
Al-Mufti, Fawaz ;
Mamdani, Muhammad ;
Saposnik, Gustavo ;
Schweizer, Tom A. ;
Macdonald, R. Loch .
NEUROSURGICAL FOCUS, 2017, 43 (05)
[7]   Risk factors for venous thromboembolism [J].
Anderson, FA ;
Spencer, FA .
CIRCULATION, 2003, 107 :I9-I16
[8]   Modifiable Risk Factors for Aneurysmal Subarachnoid Hemorrhage [J].
Andreasen, Trine H. ;
Bartek, Jiri, Jr. ;
Andresen, Morten ;
Springborg, Jacob B. ;
Romner, Bertil .
STROKE, 2013, 44 (12) :3607-3612
[9]   The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes From Aspirin to the Present Day [J].
Angiolillo, Dominick J. .
DRUGS, 2012, 72 (16) :2087-2116
[10]   Advances in Antiplatelet Therapy: Agents in Clinical Development [J].
Angiolillo, Dominick J. ;
Bhatt, Deepak L. ;
Gurbel, Paul A. ;
Jennings, Lisa K. .
AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (3A) :40A-51A